A broad, vigorous CD4 T cell response, mediated by class II human leukocyte antigens (HLAs), favors hepatitis C virus (HCV) clearance. HLA-DQB1*0301 has been associated with viral clearance in an ethnically homogeneous cohort. To validate this association and to identify other class II associations in an ethnically varied cohort, molecular class II HLA typing was performed on 200 HCV clearance and 374 matched persistently infected subjects. HLA-DQB1*0301 was weakly associated with viral clearance in combined ethnic groups (odds ratio [OR], 0.72; 95% confidence interval [CI], 0.53-0.97) but was stronger in black subjects. In white subjects, viral clearance was associated with DRB1*0101 (OR, 0.32; 95% CI, 0.17-0.60) and its DQB1*0501 haplotype, whereas viral persistence was associated with DRB1*0301 (OR, 2.36; 95% CI, 1.23-4.52) and its DQB1*0201 haplotype. These results support a role for class II alleles in the immune response to HCV and underscore the importance of studying genetic associations in an ethnically diverse cohort. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsements by the US government.
persons [4] . In addition, there are differences in the outcome of infection that follow a common source of the virus. For example, in an Irish cohort, 704 women were infected with HCV from contaminated anti-D immune globulin (Rhogam), 390 (55%) of whom became persistently infected [5] . In a subset of a similar cohort in Germany of women infected by contaminated Rhogam, 47.2% had viral persistence [6] .
Human leukocyte antigens (HLAs) are among the most integral components of the immune system. HLAs are encoded by the most polymorphic genes known in vertebrates. The HLA molecules are divided into 2 groups, classes I and II, and present foreign antigen to CD8 cytolytic T cells and to CD4 helper T cells, respectively. Studies of early HCV infection suggest that a vigorous CD4 T cell response is associated with viral clearance [7] . Thus, a strong and broad class II-restricted T helper response is especially important in an acute HCV infection. Therefore, it is plausible that certain class II antigens present HCV epitopes more effectively to CD4 helper T cells than do others. This hypothesis has been examined, but many of the results are in conflict. In a multicohort European study, an association was detected between the class II allele DQB1*0301 and viral clearance, which was duplicated in some, but not all, studies [8] [9] [10] [11] [12] [13] . Other associations also have been reported but not reproduced [12] [13] [14] [15] . These inconsistencies could be due to the small size of some studies, ethnic differences, or HCV genetic variability, thus emphasizing the need for large, multicenter studies in which ethnic-dependent variation is considered and other variables are controlled.
The association of class II antigens with HCV outcomes has not been investigated in North America and has never been pursued in large cohorts with 11 ethnic group. Here, we characterized HCV clearance and persistence in 3 independent multiethnic cohorts. By using these combined cohorts, we sought to confirm the association found in Europe with DQB1*0301 and to determine whether other class II alleles are important factors in determining HCV outcomes.
Subjects and Methods
Study subjects. Subjects in this study were participants in one of 3 studies: (1) AIDS Link to Intravenous Experience (ALIVE), an ongoing study of 2921 injection drug users (IDUs) enrolled in Baltimore from February 1988 through March 1989, as described elsewhere [16] ; (2) Multicenter Hemophilia Cohort Study, a prospectively followed-up cohort of patients with hemophilia, von Willebrand's disease, or a related coagulation disorder from 16 comprehensive hemophilia treatment centers enrolled from 1982 through 1996, as described elsewhere [17] ; and (3) Hemophilia Growth and Development Study, a continuing study of 333 children and adolescents with hemophilia who were enrolled from March 1989 through May 1990, as described elsewhere [18] . A nested case-control design was used. Case subjects had cleared viremia, as demonstrated by у2 instances separated by a minimum of 6 months, in which HCV RNA could not be detected in serum. Prior infection was substantiated by detection of HCV antibody (anti-HCV). Persistently infected control subjects selected from the same cohort had anti-HCV and HCV RNA in serum for у6 months. Control subjects were matched 2:1 to case subjects in the same cohort on the basis of HIV status, sex, geographic location (if applicable), and race. These factors were chosen since HIV status and race are determinants of viral clearance in the ALIVE cohort [4] .
Serologic testing. Subjects who tested positive for anti-HCV by a second generation HCV EIA (HCV 2.0 EIA; Ortho Diagnostic Systems) had 2 samples, separated by у6 months, assessed for HCV RNA by a branched DNA (bDNA) assay (Quantiplex HCV RNA 2.0 assay; Chiron). Subjects with 2 samples below the limit of detection by bDNA had у1 of those samples retested with the HCV COBAS Amplicor system (Roche Diagnostics) and their antibody status confirmed by a recombinant immunoblot assay (RIBA 3.0; Chiron). Only subjects with a negative HCV RNA confirmed by COBAS were defined as clearance cases. Despite ongoing exposure in some IDUs, viral clearance by this definition appeared to be stable. Subjects with 2 positive bDNA assays were eligible to be matched to the case subjects as control subjects.
HIV-1 testing was done by EIA, and positive specimens were confirmed by means of Western blot, as reported elsewhere [16] [17] [18] . Hepatitis B surface antigen (HBsAg) status was determined by use of EIA (AUSZYME; Abbott Laboratories). All assays were done according to the manufacturer's specifications, with the exception of COBAS testing in samples that contained heparin. These samples were treated with heparinase before COBAS testing by using a Roche protocol for sample preparation of heparinized plasma. All samples used for testing had been stored at Ϫ70ЊC after processing and had not been used for other assays.
HLA typing. An Epstein-Barr virus-transformed cell line was established for each subject, and DNA was extracted from these cell lines by phenol-chloroform extraction. Class II molecular typing was done by polymerase chain reaction (PCR) single-stranded conformational polymorphism analysis [19] , in combination with PCR sequence-specific primers [20] .
Statistical analysis. All analyses were done with SAS version 6.12 software (SAS Institute). The frequencies of HLA class II alleles at DQA1, DQB1, and DRB1 and homozygosity were compared between subjects who cleared HCV infection and those who had a persistent infection. Homozygosity was defined as having identical alleles at DQA1, DQB1, or DRB1. Odds ratios (ORs) were determined by conditional logistic regression and reflect the likelihood of being persistently HCV infected if carrying a specific allele. To account for the problem of significant associations arising by chance when multiple comparisons are made, we used the Bonferroni correction, which accounted for all alleles tested ( ). n p 40 This correction was not applied to DQB1*0301, since it was tested before the multiple comparisons. Alleles that had a frequency 15% and either an uncorrected or an OR 12 or !0.5 also were P р .10 stratified by race for analysis ( ). We focused on white and n p 5 [21] . ORs and P values were determined by conditional logistic regression. OR represents the likelihood of being persistently HCV infected if carrying a specific allele. "n" is the no. of alleles examined in persons who either had cleared infection or had persistent infection. CI, confidence interval; NA, not applicable; NS, not significant; OR, odds ratio; P c , Bonferroni corrected P.
black subjects, since other ethnic groups were not well represented in the study groups. In the racial stratification, Bonferroni correction accounted for the number of alleles stratified. Five haplotypes were examined, which were derived on the basis of known haplotypes composed of the significant alleles ( ). n p 5
Results
To determine the effects of HLA class II on outcome of HCV infection, we examined the alleles of 200 clearance subjects and 374 persistently infected subjects (for 26 subjects only 1 control was available) for a total of 400 and 748 alleles in each group, respectively (table 1). he study group was fairly evenly distributed between blacks and whites ( [21] . ORs and P values were determined by conditional logistic regression. OR represents the likelihood of being persistently HCV infected if carrying a specific allele. "n" is the no. of alleles examined in persons who either had cleared infection or had persistent infection. CI, confidence interval; NS, not significant; OR, odds ratio; P c , Bonferroni corrected P. ; ) and the DQA1*0501-P p .007 P p .035 c DQB1*0201-DRB1*0301 (OR, 2.48; 95% CI, 1.27-4.86; P p ; ) haplotypes were associated more strongly with .008 P p .040 c persistence in whites. In this cohort, DQA1*0501-DQB1*0201 was in strong linkage disequilibrium with DRB1*0301. Homozygosity at DQA1, DQB1, or DRB1 was not associated with HCV persistence.
Discussion
We studied 200 HCV clearance subjects and confirmed the association of DQB1*0301 with HCV clearance and also demonstrated differences in the strength of association on the basis of ethnicity. Of interest, the association was stronger in black subjects, although 2 European studies, in which the association was initially discovered, consisted primarily of European white subjects [8, 10] . Since none of the DQB1*0301 haplotypes in this study demonstrated the same association, it is likely that this allele, rather than its haplotypes, is the more important determinant of outcome.
The stronger association of DQB1*0301 with persistence in blacks may be related to inherent differences between blacks and whites or to stronger linkage of this allele to the actual disease gene in this group. The strength of association for DQB1*0301 in this study (OR, 0.72; ) was much P p .031 weaker than in the previous European studies (OR, 0.45; [11] ), perhaps because of a lower allele frequency in P p .004 our cohort, compared with that in the European cohorts. Another possibility is the higher prevalence of HCV genotypes 2 and 3 in Europe than in the United States, where HCV genotype 1 is prevalent. If DQB1*0301 were more efficient at presenting epitopes from these genotypes than from genotype 1, a greater effect would be seen in Europe. However, this is difficult to substantiate, because the genotype is unknown in most clearance cases. Third, the association may be with a gene that is tightly linked to DQB1*0301, and this linkage may be stronger in European cohorts than in the cohorts in this study. Fourth, the clearance subjects in our study may be inherently different, since our study subjects probably had repeated exposure and reinfection through multiple transfusions or injection drug use, whereas the majority of subjects in the European cohorts probably had a single infection with HCV from a transfusion. Thus, our subjects may have higher levels of virus or may have been exposed to a greater diversity of virus quasi species. DQB1*0301 may not be as effective in presenting antigen in persons with repeated exposure to the virus.
As in our study, DRB1*0101 also was identified in the cohort of Irish women as being more common in those able to clear the virus [13] . Since the Irish cohort looked only at DRB1 alleles, the potential association with DQB1*0301 or the DQB1*0501-DRB1*0101 haplotype remained unknown. Of interest, Lamonaca et al. [22] found that DRB1*0101 had a high binding affinity to 3 of the 4 highly immunogenic epitopes that they identified in the HCV genome, supporting the finding of its association with viral clearance. Since the Irish cohort was limited to white women of European descent and since our study showed the association only in the white subjects, this allele may be less important for clearance in blacks or it may be more tightly linked to the true disease gene in whites. Alternatively, the lower frequency of this allele in blacks may decrease the power to find an association.
The association of DRB1*0301 with viral persistence was significant only in whites after use of the Bonferroni correction, and the same relationship was identified in a cohort from Thailand [12] . Unfortunately, the significance of this allele in the Thai study was difficult to determine, because it was limited to 43 clearance subjects and 57 unmatched persistently infected subjects. Our study, in a different ethnic population, also suggests that the DRB1*0301 haplotypes with DQB1*0201 and DQA1*0501 influence viral persistence in whites. Of interest, this allele also has been associated with autoimmune hepatitis [23] and with chronic HCV, compared with that in uninfected control subjects [24] . It also is possible that this allele is linked to another gene associated with viral persistence.
It was reasonable to postulate that homozygous persons have fewer alleles with which to present immunogenic HCV epitopes, resulting in a narrower protective response. Although our study was much larger than that of Thursz et al. [11] , we also did not find a class II heterozygote advantage with HCV clearance. The failure to confirm this hypothesis may be due to insufficient power to detect the association, although a study larger than this one may not be undertaken. It also suggests that perhaps other unidentified determinants of viral clearance, working in conjunction with class II alleles, are also important. For example, the immune cells involved in the very early response in the liver also may have an important role in establishing the outcome of an acute HCV infection.
In this multiethnic study, we showed differential associations of DQB1*0301, DRB1*0101, and DRB1*0301 with associated haplotypes in ethnic groups. Our lack of associations with other class II alleles is also an equally important finding, since we studied a large number of people in ethnic groups that differ from those previously studied. Weak HLA effects could still potentially be overlooked. Nevertheless, targeting the epitopes presented by DQB1*0301 and DRB1*0101 for vaccines that will boost the T helper response may be effective in a wide range of ethnic groups.
Although the effects of class II alleles identified in this study are important in determining viral outcomes, this accounts for only a small percentage of the persons in the persistence and clearance groups. Thus, other genes, acting either alone or in concert with other genetic determinants and environmental factors, need to be identified to elucidate the differences in the host response to this rapidly mutating virus.
